Clinical trials: Mixed Oligoastrocytoma
Glioblastoma, Gliosarcoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00667394
- Testing
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Central nervous system (CNS) malignancies are the second most common malignancy and the most common solid tumor of childhood, including adolescence.
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma
- Trial name
- NCT01884740
- Testing
- SIACI of Erbitux and Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Glioma of Brain, Astrocytoma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma
- Trial name
- rQNestin (NCT03152318)
- Testing
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors
Topotecan in Treating Patients With Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain…
- Trial name
- NCT00003372
- Testing
- topotecan hydrochloride
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00004259
- Testing
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy
- Where
- 92 sites in United States
- Volunteers
- 230 people
- Sponsor
- Radiation Therapy Oncology Group
High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in patients with recurrent glioblastoma and has been…
- Conditions
- High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO)
- Trial name
- NCT01339039
- Testing
- Plerixafor, Bevacizumab, Surgery
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Patrick Y. Wen, MD
Glioma, Pilocytic Astrocytoma
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics…
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT02372409
- Testing
- MRI-guided laser ablation, Doxorubicin, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Oligoastrocytoma, Mixed, Anaplastic Oligodendroglioma
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Rationale: Standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes radiation and chemotherapy. However, due to the potential long-term central nervous system toxicity from radiation, researchers…
- Trial name
- NCT00362570
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Adult Diffuse Astrocytoma, Adult Mixed Glioma
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients.
- Conditions
- Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor
- Trial name
- NCT01635283
- Testing
- tumor lysate-pulsed autologous dendritic cell vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioma, Malignant Glioma
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically…
- Conditions
- Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma
- Trial name
- NCT02924038
- Testing
- IMA950, poly-ICLC, Varlilumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nicholas Butowski
Central Nervous System Tumors, Brain Tumor
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00400816
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Cleveland Clinic
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Glioma, Glioblastoma Multiforme
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine IL13 and a toxin from the bacterium…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00064779
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Glioma, Astrocytoma
Prolonged Daily Temozolomide for Low-Grade Glioma
The purpose of this trial is to determine the effects (good and bad) temozolomide has on patients with low-grade glioma. It will also determine whether temozolomide is effective in preventing or delaying future tumor growth.
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma
- Trial name
- NCT00165360
- Testing
- Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute